Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3209068 | Journal of the American Academy of Dermatology | 2009 | 4 Pages |
Abstract
Intravascular lymphoma is an uncommon, very aggressive extranodal non-Hodgkin lymphoma that most frequently involves the skin and central nervous system. Most cases are of B-cell origin; T-cell phenotype is extremely rare. Malignant cells proliferate within the lumens of capillaries, arterioles, venules, and small arteries; vascular occlusion is responsible for the clinical signs and symptoms. The prognosis of this high-grade B-cell lymphoma has improved since the introduction of the anti-CD20 monoclonal antibody, rituximab. We describe a case of B-cell intravascular lymphoma successfully treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Barbara Horváth, Judit Demeter, Nóra Erős, Judit Hársing, Judit Csomor, András Matolcsy, Gyula Bottlik, Gabriella Győri, Márta Marschalkó, Sarolta Kárpáti,